Trials / Recruiting
RecruitingNCT04342026
Role of the Environment and Endocrine Disruptors in Child Cryptorchidism
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,452 (estimated)
- Sponsor
- University Hospital, Montpellier · Academic / Other
- Sex
- Male
- Age
- 1 Month – 18 Years
- Healthy volunteers
- Not accepted
Summary
Cryptorchidism is the most frequent congenital defect of the male newborn. It requires surgery in childhood, increases the risk of fertility disorders and cancer. As a major public health objective, it's the subject of numerous recommendations. Its frequency is increasing in some countries faster than a single genetic cause could not explain it. It may occurs in a geographic cluster. The cause of cryptorchidism involves genetic, hormonal and environmental factors. Animal studies suggest that endocrine disruptors interfere with fetal testicular migration. The aim of the study is to find out if some environmental exposition may be associated with cryptorchidism.
Detailed description
Cryptorchidism is the most frequent congenital defect of the male newborn. It requires surgery in childhood, increases the risk of fertility disorders and cancer. As a major public health objective, it's the subject of numerous recommendations. Its frequency is increasing in some countries faster than a single genetic cause could not explain it. It may occurs in a geographic cluster. The cause of cryptorchidism involves genetic, hormonal and environmental factors. Animal studies suggest that endocrine disruptors interfere with fetal testicular migration. The aim of the study is to find out if some environmental exposition may be associated with cryptorchidism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Measure of the exposure of parent of male with /without cryptorchidism to endocrine disruptors | Measure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy) |
Timeline
- Start date
- 2020-04-16
- Primary completion
- 2027-10-15
- Completion
- 2028-04-15
- First posted
- 2020-04-10
- Last updated
- 2025-10-03
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04342026. Inclusion in this directory is not an endorsement.